PER-030-10
Completed
未知
A PHASE I/II DOSE-FINDING STUDY OF HIGH-DOSE FLUCONAZOLE TREATMENT IN AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS
INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS, SOCIAL & SCIENTIFIC SYSTEMS, INC,,0 sites0 target enrollmentJuly 6, 2010
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- -B24 Unspecified human immunodeficiency virus [HIV] disease
- Sponsor
- INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS, SOCIAL & SCIENTIFIC SYSTEMS, INC,,
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •CM documented either by a positive CSF cryptococcal culture, a positive CSF India ink preparation, or a positive CSF cryptococcal antigen latex agglutination test within 7 days prior to entry. More information on this criterion can be found in the protocol.
- •CSF collection for quantitative cryptococcal culture within 72 hours prior to study entry or planned to be performed at study entry
- •HIV\-1 infection documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by or within 10 days after study entry by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, by HIV\-1 antigen, or by plasma HIV\-1 RNA viral load. More information on this criterion can be found in the protocol.
- •Ability to take oral medications. NOTE: Administration of fluconazole tablets via nasogastric tube is permitted.
- •For patients with a co\-morbid complication of HIV, including opportunistic infections, reasonable certainty that the site investigator will be able to perform CSF sampling and manage expected study drug toxicities. More information on this criterion can be found in the protocol.
- •For female participants of reproductive potential (defined as girls who have reached menarche or women who have not been post\-menopausal for at least 24 consecutive months \[i.e., who have had menses within the preceding 24 months, or have not undergone surgical sterilization, for example, a hysterectomy, or bilateral oophorectomy or salpingotomy]) a negative serum or urine pregnancy test result must be obtained within 2 days prior to study entry
- •All participants must agree not to participate in the conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization).
- •If participating in sexual activity that could lead to pregnancy, female study participants must agree to the simultaneous use of two forms of contraception (listed in protocol) during sexual activity, and male study participants must agree to use a condom during such sexual activity. This requirement continues while the study participant is on study treatment and for 6 weeks after fluconazole has been discontinued. More information on this criterion can be found in the protocol.
- •Study participants who are not of reproductive potential (defined as women who have been post\-menopausal for at least 24 consecutive months, women who have undergone surgical sterilization \[e.g., hysterectomy, or bilateral oophorectomy or salpingectomy], or men who have documented azoospermia) are eligible without the requirement to use contraceptives. More information on this criterion can be found in the protocol.
- •Willingness and ability to adhere to dose schedules and mandatory procedures
Exclusion Criteria
- •Expected survival of 2 weeks or less, in the opinion of the site investigator and, if available, the primary care provider
- •For patients with a comorbid complication of HIV, anticipated difficulty, in the opinion of the site investigator, in judging response to study treatment as a result of the comorbid complication or the drugs used to treat it
- •Breastfeeding
- •prior episode of CM, either as indicated by patient or as noted in patient medical records
- •Use of certain drugs within specified time periods. More information on this criterion can be found in the study protocol.
- •For candidates who are currently taking nevirapine, the inability to discontinue nevirapine and replace it with a drug that does not have fluconazole drug interactions at or by study entry in the event they are randomized to a high\-dose fluconazole treatment arm. More information on this criterion can be found in the study protocol.
- •Known allergy, sensitivity to, or intolerance of fluconazole or other imidazole or triazole compounds or to ampho B or other components of the standard of care ampho B based regimen
- •History of clinically significant cardiac disease, in the opinion of the site investigator, including symptoms of ischemia, coronary artery disease, congestive heart failure, or arrhythmia
- •ECG with QTc interval greater than 450 msec within 7 days prior to study entry. More information on this criterion can be found in the study protocol.
- •History of CNS disorder (excluding mood disorders) or concurrent CNS disorder(s) that, in the opinion of the investigator, would interfere with assessment of efficacy (e.g., ability to perform CSF sampling) such as lymphoma, neurocysticercosis, or toxoplasmosis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
High-Dose Fluconazole for the Treatment of CM in HIV-infected PeopleCTRI/2013/04/003545Division of AIDS DAIDS NIH USA Division of AIDS DAIDS NIH USA192
Active, not recruiting
Not Applicable
A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - NDPatients with primary breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187EUCTR2010-020772-38-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
Active, not recruiting
Not Applicable
A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin To Patients With Advanced MalignanciesAdvanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative chemotherapy.MedDRA version: 8.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2006-006515-76-GBOncolytics Biotech Inc
Active, not recruiting
Phase 1
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous systemEUCTR2018-001404-11-ITGENENTA SCIENCE SR21
Active, not recruiting
Not Applicable
PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMAHigh-risk medulloblastomaMedDRA version: 16.0Level: PTClassification code 10027107Term: MedulloblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004842-14-FRInstitut de cancérologie Gustave Roussy